Navigation Links
Multiple lipomas within jejunal duplication cyst
Date:5/7/2010

Lipoma of the small intestine is a benign tumor of mesenchymal origin which is mostly found by chance during gastrointestinal investigation. Invaginations account for 2/3 of small bowel occlusion caused by up to 80% of tumors and the lipoma is the most frequent benign tumor that causes invagination in its submucous polypoid and it is in more or less scissile form. However, multiple lipomas within the intestinal duplication canal as a predominant cause of partial intestinal obstruction is an exceptional clinical scenario.

A research article to be published on May 7, 2010 in the World Journal of Gastroenterology addresses this question. The research team from Department of Gastroenterology, Renmin Hospital of Wuhan University, reported a case of a 68-year-old man with a 10-d history of abdominal bloating after meals caused by intussusception due to a small intestine lipomatous lesion located in the jejunal duplication cyst.

Multiple lipomas within jejunal duplication cysts are rare and difficult to diagnose before surgery. This case highlights small intestinal lipoma, though uncommon, should be included in the differential diagnosis of intestinal obstruction and appropriate examination methods should be chosen. Such a case found by double-balloon endoscopy is an example to remind doctors to be vigilant in diagnosing patients with intestinal obstruction and in choosing appropriate examinations.


'/>"/>

Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Catching multiple sclerosis before it strikes
2. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
3. Statins may slow progression of multiple sclerosis, new study finds
4. Free CME/CE Lecture and Workshop on Multiple Sclerosis: Boise, ID
5. Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center
6. Damaka Delivers Advanced Sweeping™ Capability of Live Sessions Across Multiple Devices Over WiFi, 3G and 4G Networks
7. Discovery May Lead to Better Multiple Sclerosis Treatments
8. Kineta Awarded NIH Grant to Complete Preclinical Studies on Type 1 Diabetes / Multiple Sclerosis Drug Candidate
9. Sunwin International & WILD Flavors Receive GRAS Letters of No Objection from FDA Validating Safety of Multiple Sunwin Stevia Extracts
10. 'Miracles For MSA' Proclaims March as Multiple System Atrophy Awareness Month
11. MOVE IT! Join the Movement to End Multiple Sclerosis During MS Awareness Week March 8-14, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... ... 12, 2017 , ... Vohra Chief Medical Officer Dr. Shark ... skilled nursing facility medical directors and other clinicians at various events in October. ... "At many of these conferences we get to educate other physicians, facility nurses, ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
Breaking Medicine Technology: